Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
- Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
- Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
- The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
- "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.